Trial Profile
Phase I/II clinical trial of novel peptide-based cancer vaccine IMA901 for patients with advanced renal cell carcinoma.
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs IMA 901 (Primary) ; Cyclophosphamide; Granulocyte-macrophage colony-stimulating factors
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2023 Long-term follow up results (n=10) assessing safety of IMA901 in Japanese patients with advanced renal cell cancer, published in the International Journal of Urology.
- 16 May 2017 Results (n=10) presented at the 112th Annual Meeting of the American Urological Association
- 30 Dec 2011 New trial record